- McCormick, Frank;
- Kashiyama, T;
- Oda, K;
- Ikeda, Y;
- Shiose, Y;
- Hirota, Y;
- Inaba, K;
- Makii, C;
- Kurikawa, R;
- Miyasaka, A;
- Koso, T
DS-7423, a novel, small-molecule dual inhibitor of phosphatidylinositol-3- kinase (PI3K) and mammalian target of rapamycin (mTOR), is currently in phase I clinical trials for solid tumors. Although DS-7423 potently inhibits PI3Kα (IC50 = 15.6 nM) and mTOR